

AN2Therapeutics

\$70 Million
Follow-On Offering

LEERINK 
PARTNERS
Joint Bookrunner
August 2023

Leerink Partners Serves as Joint Bookrunner for AN2 Therapeutics' (Nasdaq: ANTX) \$70 Million Follow-On Offering

Key Transaction Highlights

- Underwritten confidentially marketed deal that launched on August 14th pre-open and priced on August 15th post-close
- Deal consisted of 7,777,778 shares of common stock at a price of \$9.00 per share, representing a 4.2% premium to last sale
- AN2 Therapeutics intends to use the net proceeds from this offering for working capital and general corporate purposes, including general and administrative expenses, research and development expenses and capital expenditures.
- Participation from new and existing investors, including RA Capital Management, TCGX, Frazier Life Sciences, Marshall Wace, Adage Capital Partners LP, Avidity Partners, Janus Henderson Investors and Surveyor Capital (a Citadel company)
- This is Leerink Partners' 2nd bookrun offering for AN2 Therapeutics and 38th equity bookrun offering in 2023.

If you would like to unsubscribe from this distribution, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF LEERINK PARTNERS LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON
53 State Street
40th Floor
Boston, MA 02109

CHARLOTTE
2151 Hawkins Street
Suite 1025
Charlotte, NC 28203

NASHVILLE
40 Burton Hills Boulevard
Suite 200
Nashville, TN 37215

NEW YORK
1301 Avenue of the Americas
12th Floor
New York, NY 10019

SAN FRANCISCO
255 California Street
12th Floor
San Francisco, CA 94111